Vaxcyte, Inc. — Director's Dealing 2021

Oct 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-10-26

Reporting Person: Fairman Jeff (VP, Research)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-26	Common Stock	M	4750	$1.79	Acquired	9894	Direct
2021-10-26	Common Stock	S	4750	$22.69	Disposed	5144	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-26	Stock Option (right to buy)	$1.79	M	4750	Disposed	2027-05-17	Common Stock (4750)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	341227	Indirect
Common Stock	50000	Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $22.54 to $22.855. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The shares subject to the option are fully vested and exercisable.